[1] [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. ［J］. A Cancer Journal for Clinicians, 2018, 68(6): 394-424.

[2] [2] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics, 2012［J］. A Cancer Journal for Clinicians, 2011, 61(2): 69-90.

[3] [3] LARSEN J E, PAVEY S J, PASSMORE L H, et al. Gene expression signature predicts recurrence in lung adenocarcinoma［J］. Clinical Cancer Research, 2007, 13(10): 2946-2954.

[4] [4] PAO W, GIRARD N. New driver mutations in non-small-cell lung cancer［J］. Lancet Oncology, 2011, 12(2): 175-180.

[5] [5] LI T, KUNG H J, MACK P C. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies［J］. Journal of Clinical Oncology, 2013, 31(8): 1039-1049.

[6] [6] LEVY B, HU Z I, CORDOVA K N, et al. Clinical uility of liquid diagnostic platforms in non-small cell lung cancer［J］. Oncologist, 2016, 21(9): 1121-1130.?

[9] [9] SOCINSKI M A, PENNELL N A. Best practices in treatment selection for patients with advanced NSCLC［J］. Cancer Control Journal of the Moffitt Cancer Center, 2016, 23(4 Suppl): 2-14.

[10] [10] PAN Q, SHAI O, LEE L J, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing［J］. Nature Genetics, 2008, 40(12): 1413-1415.

[11] [11] HUANG D W, SHERMAN B T, LEMPICKI R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources［J］. Nature Protocols, 2008, 4(1): 44-57.

[12] [12] PONTéN F, SCHWENK J M, ASPLUND A, et al. The human protein atlas as a proteomic resource for biomarker discovery［J］. Journal of Internal Medicine, 2011, 270(5): 428-446.

[13] [13] COX C E, SALUD C J, CANTOR A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis［J］. Journal of the American College of Surgeons, 2001, 193(6): 593-600.

[14] [14] DUPONT E, COX C, SHIVERS S, et al. Learning curves and breast cancer lymphatic mapping: institutional volume index［J］. Journal of Surgical Research, 2001, 97(1): 92-96.

[15] [15] LUO T, WANG L, WU P, et al. Downregulated vimentin and upregulated e-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?［J］. Neoplasma, 2017, 64(5): 693-699.

[17] [17] ZHU Y, SPITZ M R, LEI L, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility［J］. Cancer Research, 2001, 61(21): 7825-7829.

[18] [18] YLISIRNI? S, H?YHTY? M, TURPEENNIEMI-HUJANEN T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer–TIMP-1 as a prognostic marker［J］. Anticancer Research, 2000, 20(2B): 1311-1316.

[23] [23] SHI Y, DUAN Z, ZHANG X, et al. Down-regulation of the let-7i facilitates gastric cancer invasion and metastasis by targeting COL1A1［J］. Protein & cell, 2019, 10(2): 143-148.

[25] [25] LIU J, SHEN J X, WU H T, et al. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target［J］. Discovery Medicine, 2018, 25(139): 211-223.

[26] [26] LV J, GUO L, WANG J H, et al. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett’s esophagus［J］. World Journal of Gastroenterology, 2019, 25(2): 233-244.

[27] [27] MA H P, CHANG H L, BAMODU O A, et al. Collagen 1A1 (COL1A1) is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis［J］. Cancers, 2019, 11(6): 786.

[29] [29] KOENIG A, MUELLER C, HASEL C, et al. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells［J］. Cancer Research, 2006, 66(9): 4662-4671.

[30] [30] IMAMICHI Y, KONIG A, GRESS T, et al. Collagen type I-induced smad-interacting protein 1 expression downregulates e-cadherin in pancreatic cancer［J］. Oncogene, 2007, 26(16): 2381-2385.

[31] [31] SHINTANI Y, MAEDA M, CHAIKA N, et al. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling［J］. American Journal of Respiratory Cell and Molecular Biology, 2008, 38(1): 95-104.

[35] [35] BHATTACHARYA S D, MI Z, KIM V M, et al. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model［J］. Annals of Surgery, 2012, 255(2): 319-325.

[36] [36] WU X L, LIN K J, BAI A P, et al. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells［J］. World Journal of Gastroenterology, 2014, 20(30): 10440-10448.

[40] [40] WAI P Y, KUO P C. The role of osteopontin in tumor metastasis［J］. Journal of Surgical Research, 2004, 121(2): 228‐241.